Takada Ayato
Nihon Rinsho. 2016 Dec;74(12):2080-2085.
Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever (Ebola virus disease: EVD) in humans and nonhuman primates with case fatality rates of up to 90%. No effective prophylaxis or treatment for EVD is yet commercially available. The latest out- break of EVD in West Africa has highlighted the urgent need for the development of thera- peutics and diagnostics. This outbreak has indeed accelerated efforts to develop antiviral countermeasures and unapproved vaccines, drugs, and diagnostics were used during the outbreak, some of which have undergone clinical trials. This article reviews recent advances on the development of therapeutics and diagnostics for EVD, particularly focusing on the util- ity of virus-specific monoclonal antibodies.
埃博拉病毒是丝状病毒科的成员，可导致人类和非人类灵长类动物患上严重出血热（埃博拉病毒病：EVD），病死率高达90%。目前尚无针对埃博拉病毒病的有效预防或治疗方法可供商业使用。西非最近爆发的埃博拉病毒病凸显了开发治疗方法和诊断手段的迫切需求。此次疫情确实加速了抗病毒对策的研发，疫情期间使用了未经批准的疫苗、药物和诊断方法，其中一些已经进行了临床试验。本文综述了埃博拉病毒病治疗方法和诊断手段的最新进展，尤其关注病毒特异性单克隆抗体的应用。
